# Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients

Study · id `cardio:ct-nct03601039` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03601039](<https://clinicaltrials.gov/study/NCT03601039>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03601039

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

## Technical summary

Registry record NCT03601039. Allocation not applicable; no masking; primary purpose treatment. Start 2018-08-25 (actual); primary completion 2020-08-28 (actual). Results posted on 2026-03-10.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 165 participants (enrolled count; ClinicalTrials.gov record NCT03601039, source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)
- Started: 2018-08-25 (actual) (ClinicalTrials.gov record NCT03601039, source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)
- Primary completion: 2020-08-28 (actual) (ClinicalTrials.gov record NCT03601039, source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)
- Completion: 2024-08-30 (actual) (ClinicalTrials.gov record NCT03601039, source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)
- Results first posted: 2026-03-10 (ClinicalTrials.gov record NCT03601039, source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03601039, source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03601039-2026-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients
- Condition: Heart Septal Defects, Atrial
- Condition: Atrial Septal Defect
- Intervention (Device): Absnow Absorbable ASD Closure System
- Lead sponsor: Lifetech Scientific (Shenzhen) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Lifetech Scientific (Shenzhen) Co., Ltd. (`cardio:org-lifetech-scientific-shenzhen-co-ltd`)

## Provenance

Content hash: 0446be557f79817cdb44f987461f302df8ab3887e95c8a83c47b91f443bd5cfa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
